Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 207

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 207
---
 fair value of the Class B Placement Agent Common Stock Warrants were estimated using the Black -Scholesoption pricing model with the following assumptions:

| Volatility              |     |  144 | % |
| Expected term (years)   |     |    5 |   |
| Risk-free interest rate |     | 2.69 | % |
| Expected dividend yield |     |  0.0 | % |

Class C Pre-Funded Warrants In connection with the February 2023 Public Offering, the Company issued pre -fundedwarrants to purchase up to 699shares of common stock at an exercise price of $0.048 per share. Between February 14, 2023 and April 6, 2023, the Company received notices of cash exercise for the Class C Pre -FundedWarrants issued in connection with the February 2023 Public Offering for 699shares of common stock at a total purchase price of $33.64. As of December 31, 2024, there were no Class C Pre -FundedWarrants outstanding. Class C Common Stock Warrants In connection with the February 2023 Public Offering, the Company issued 6,450,000 Class C Common Stock Warrants to purchase up to 13,438shares of common stock at an exercise price of $2,572.80 per share, valued on the public offering purchase date in the aggregate at $13,996,500 and included in the issuance costs of the public offering and treated as a liability. The warrants were exercisable immediately upon issuance, provide for a cash, cashless exercise right or an alternative cashless exercise right for 0.4shares of common stock per Class C Common Stock Warrant and expire on February 14, 2028. The Company evaluated the Class C Common Stock Warrants under ASC 815 -40and concluded that they do not meet the criteria to be classified in stockholders’ equity and accounted for the Class C Common Stock Warrants as current liabilities. The Company concluded that the multiplier of 0.4shares of common stock per Class C Common Stock Warrant used in the alternative cashless exercise precludes the Class C Common Stock Warrants from being considered indexed to the Company’s stock. The Company recorded the Class C Common Stock Warrants as current liabilities on the balance sheet at fair value, with subsequent changes in their respective fair values recognized in the consolidated statements of operations at each reporting date. Estimating fair values of liability -classifiedfinancial instruments